Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay

Giuseppe Viale, Jennifer Paterson, Miriam Bloch, George Csathy, David Allen, Patrizia Dell'Orto, Gitte Kjærsgaard, Yaron Y. Levy, Jan Trøst Jørgensen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In breast cancer the human epidermal growth factor receptor 2 (HER2) is an important target for a number of different HER2 inhibitors. Different slide-based assays are available for assessment of treatment eligibility, which include fluorescence in situ hybridization (FISH) or other in situ hybridization (ISH) methods for assessment of the HER2 gene status. Here we report a summary of the validation data on HER2 IQFISH pharmDx™ (Dako Omnis), a newly developed assay for the automated staining platform Dako Omnis. The assay uses a non-toxic buffer that significantly reduces the hybridization time, which results in a total turnaround time of 3½ to 4 h from deparaffinization to counting of the gene and centromere signals. The data reported in the current summary covers method comparison, assessment of staining quality, observer-to-observer reproducibility as well as reproducibility within and between laboratories. Based on data from the different studies it was concluded that HER2 IQFISH pharmDx (Dako Omnis) is a reliable and robust assay with a high precision that is at least comparable to the manual HER2 IQFISH pharmDx™ assay and the PathVysion® HER-2 DNA Probe Kit.

Original languageEnglish
Pages (from-to)735-742
Number of pages8
JournalPathology Research and Practice
Volume212
Issue number8
DOIs
Publication statusPublished - Aug 1 2016

Fingerprint

Breast Neoplasms
Staining and Labeling
erbB-1 Genes
Centromere
DNA Probes
Fluorescence In Situ Hybridization
In Situ Hybridization
human ERBB2 protein
Buffers
Genes

Keywords

  • Automation
  • Breast cancer
  • Companion diagnostic
  • HER2
  • IQFISH

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology

Cite this

Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay. / Viale, Giuseppe; Paterson, Jennifer; Bloch, Miriam; Csathy, George; Allen, David; Dell'Orto, Patrizia; Kjærsgaard, Gitte; Levy, Yaron Y.; Jørgensen, Jan Trøst.

In: Pathology Research and Practice, Vol. 212, No. 8, 01.08.2016, p. 735-742.

Research output: Contribution to journalArticle

Viale, Giuseppe ; Paterson, Jennifer ; Bloch, Miriam ; Csathy, George ; Allen, David ; Dell'Orto, Patrizia ; Kjærsgaard, Gitte ; Levy, Yaron Y. ; Jørgensen, Jan Trøst. / Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay. In: Pathology Research and Practice. 2016 ; Vol. 212, No. 8. pp. 735-742.
@article{efcb72e17eea4f31b8040b43eb61fc69,
title = "Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay",
abstract = "In breast cancer the human epidermal growth factor receptor 2 (HER2) is an important target for a number of different HER2 inhibitors. Different slide-based assays are available for assessment of treatment eligibility, which include fluorescence in situ hybridization (FISH) or other in situ hybridization (ISH) methods for assessment of the HER2 gene status. Here we report a summary of the validation data on HER2 IQFISH pharmDx™ (Dako Omnis), a newly developed assay for the automated staining platform Dako Omnis. The assay uses a non-toxic buffer that significantly reduces the hybridization time, which results in a total turnaround time of 3½ to 4 h from deparaffinization to counting of the gene and centromere signals. The data reported in the current summary covers method comparison, assessment of staining quality, observer-to-observer reproducibility as well as reproducibility within and between laboratories. Based on data from the different studies it was concluded that HER2 IQFISH pharmDx (Dako Omnis) is a reliable and robust assay with a high precision that is at least comparable to the manual HER2 IQFISH pharmDx™ assay and the PathVysion{\circledR} HER-2 DNA Probe Kit.",
keywords = "Automation, Breast cancer, Companion diagnostic, HER2, IQFISH",
author = "Giuseppe Viale and Jennifer Paterson and Miriam Bloch and George Csathy and David Allen and Patrizia Dell'Orto and Gitte Kj{\ae}rsgaard and Levy, {Yaron Y.} and J{\o}rgensen, {Jan Tr{\o}st}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.prp.2016.06.002",
language = "English",
volume = "212",
pages = "735--742",
journal = "Pathology Research and Practice",
issn = "0344-0338",
publisher = "Elsevier GmbH",
number = "8",

}

TY - JOUR

T1 - Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay

AU - Viale, Giuseppe

AU - Paterson, Jennifer

AU - Bloch, Miriam

AU - Csathy, George

AU - Allen, David

AU - Dell'Orto, Patrizia

AU - Kjærsgaard, Gitte

AU - Levy, Yaron Y.

AU - Jørgensen, Jan Trøst

PY - 2016/8/1

Y1 - 2016/8/1

N2 - In breast cancer the human epidermal growth factor receptor 2 (HER2) is an important target for a number of different HER2 inhibitors. Different slide-based assays are available for assessment of treatment eligibility, which include fluorescence in situ hybridization (FISH) or other in situ hybridization (ISH) methods for assessment of the HER2 gene status. Here we report a summary of the validation data on HER2 IQFISH pharmDx™ (Dako Omnis), a newly developed assay for the automated staining platform Dako Omnis. The assay uses a non-toxic buffer that significantly reduces the hybridization time, which results in a total turnaround time of 3½ to 4 h from deparaffinization to counting of the gene and centromere signals. The data reported in the current summary covers method comparison, assessment of staining quality, observer-to-observer reproducibility as well as reproducibility within and between laboratories. Based on data from the different studies it was concluded that HER2 IQFISH pharmDx (Dako Omnis) is a reliable and robust assay with a high precision that is at least comparable to the manual HER2 IQFISH pharmDx™ assay and the PathVysion® HER-2 DNA Probe Kit.

AB - In breast cancer the human epidermal growth factor receptor 2 (HER2) is an important target for a number of different HER2 inhibitors. Different slide-based assays are available for assessment of treatment eligibility, which include fluorescence in situ hybridization (FISH) or other in situ hybridization (ISH) methods for assessment of the HER2 gene status. Here we report a summary of the validation data on HER2 IQFISH pharmDx™ (Dako Omnis), a newly developed assay for the automated staining platform Dako Omnis. The assay uses a non-toxic buffer that significantly reduces the hybridization time, which results in a total turnaround time of 3½ to 4 h from deparaffinization to counting of the gene and centromere signals. The data reported in the current summary covers method comparison, assessment of staining quality, observer-to-observer reproducibility as well as reproducibility within and between laboratories. Based on data from the different studies it was concluded that HER2 IQFISH pharmDx (Dako Omnis) is a reliable and robust assay with a high precision that is at least comparable to the manual HER2 IQFISH pharmDx™ assay and the PathVysion® HER-2 DNA Probe Kit.

KW - Automation

KW - Breast cancer

KW - Companion diagnostic

KW - HER2

KW - IQFISH

UR - http://www.scopus.com/inward/record.url?scp=84991224418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991224418&partnerID=8YFLogxK

U2 - 10.1016/j.prp.2016.06.002

DO - 10.1016/j.prp.2016.06.002

M3 - Article

VL - 212

SP - 735

EP - 742

JO - Pathology Research and Practice

JF - Pathology Research and Practice

SN - 0344-0338

IS - 8

ER -